| Name | Title | Contact Details |
|---|
Versante International is a Oakland, CA-based company in the Healthcare, Pharmaceuticals, and Biotech sector.
General Medical Group is a Houston, TX-based company in the Healthcare, Pharmaceuticals, and Biotech sector.
Monroe County Medical Center is a Tompkinsville, KY-based company in the Healthcare, Pharmaceuticals, and Biotech sector.
The NCH Healthcare System is a not-for-profit multi-facility healthcare system located in Naples, Florida. The system includes two hospitals (NCH Healthcare System – Downtown Naples Hospital and NCH Healthcare System – North Naples Hospital) with a total of 681 beds collaborating with 630 physicians to care for more than 32,000 patients each year. Outpatient facilities include Walk-in Centers, Wellness Centers, Rehabilitation Centers, Wound Care Facilities, and Infusion Centers in Naples, North Naples, Marco Island, Bonita Springs, and Estero. NCH`s Emergency Departments and outpatient facilities had over 120,000 visits for the past two years. Caring for all ages in the communities it serves, NCH performs almost 500 open heart surgeries and 3,400 newborn deliveries each year.
Enterin is pioneering the medical community`s understanding of the link between infections, dysfunction of the enteric nervous system (ENS) of the gut, and the early onset and chronic progression of neurodegenerative disease. We are leveraging years of research to become the first company in the world to develop a novel drug that repairs the dysfunctional gut-brain axis in patients with neurodegenerative disease. Our lead compound, ENT-01 (also known as kenterin), displaces membrane-bound alpha- synuclein (αS) aggregates from nerve cells in the ENS and improves neural signaling between the gut and the brain in preclinical models of Parkinson`s disease. In the gut, this results in improved motility. We are now progressing this drug through clinical trials in an attempt to reverse the constipation of Parkinson`s disease. Our long-term mission is to become the world leader in developing pharmaceutical therapies that repair the gut-brain axis.